Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aquivia Health vs Bliv

Aquivia Health
Graded #81

Higher grade

vs+5.900000000000006
Bliv
Graded #187

Lower grade

The verdict

Aquivia Health takes it — 72.2/100 to 66.3/100.

Aquivia Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Aquivia Health is a clinician-led, self-pay telehealth platform offering compounded GLP-1 therapy with the option to step up to branded Ozempic or Zepbound — an unusual side-by-side most compounded…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAquivia Health +15
86
71
Dose & formulationAquivia Health +21
85
64
Clinical oversightBliv +18
64
82
Labs & monitoringEven
53
53
FulfillmentAquivia Health +6
71
65
Contract termsAquivia Health +10
55
45
Aquivia Health · left barBliv · right bar

The numbers

MetricAquivia HealthBliv
WeighScore72.2/10066.3/100
GradeCC
Scorecard rank#81#187
Semaglutide$149/mo$116/mo (as low as, varies by plan and eligibility, compounded)
Tirzepatide$179/mo$199/mo (as low as, varies by plan and eligibility, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Aquivia Health

Graded #81 · C

Strengths

  • Clinical care provided by Open Loop Healthcare Partners, PC — a reused, verified MSO network
  • Named leadership: Steven Bishop MD (CMO), Phillip Gray PharmD (Chief Pharmacist), Tom Foster (President)
  • Itemized public pricing: compounded semaglutide $149/mo, tirzepatide $179/mo, Ozempic $1,299, Zepbound $1,399
  • Both compounded and branded GLP-1s offered side by side — unusual for a compounded provider
  • Self-pay model with no insurance required and no separate consultation fee

Where it loses points

  • No public list of states served — you must complete intake to learn if your state qualifies
  • No named 503A compounding pharmacy partner, limiting licensure verification
  • No LegitScript, PCAB, or BBB trust badges visible
  • Brand confusion: site schema names 'CatalystMD' while the customer-facing brand is Aquivia Health
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Bliv

Graded #187 · C

Strengths

  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • The advertised rates are 'as low as' figures footnoted 'based on plan structure and eligibility', and the plan selector sits behind the medical intake — the rate you are offered is not knowable before you hand over a medical history
  • A $24.99 provider consultation fee is charged on top, and the refund policy deducts $200 for 'clinical coordination and account setup'
  • The homepage advertises 'no long-term commitments or cancellation fees' while the terms require the membership fee to be paid 'in a single sum', call it non-refundable and refer to a 'Membership Term'
  • The only figure smaller than the advertised rate is a $29 CareCredit/Klarna instalment, which is a financing payment rather than the price of a month of medication
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard